Satya to present preclinical profile of its PARG inhibitors at the 2024 American Association for Cancer Research (AACR) Annual Meeting – April 5-10, San Diego, CA

On March 21, 2024 Satya reported to present preclinical profile of its PARG inhibitors at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting – April 5-10, San Diego, CA (Press release, SATYA Pharma Innovations, MAR 21, 2024, View Source [SID1234641350]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

March 21, 2024
3:31 pm
Abstract title

Preclinical profile of novel and potent small molecule inhibitors of PARG

Poster number

7112

Session title

DNA Damage and Repair

Session date and time

April 10, 9:00 AM – 12:30 PM

Session category

Experimental and Molecular therapeutics

Abstract title: Preclinical profile of novel and potent small molecule inhibitors of PARG

Abstract:
Poly(ADP-ribose) glycohydrolase (PARG) is primary enzyme involved in the dePARylation process of DNA repair, specifically in the single strand break repair (SSBRs). PARG is a macrodomain protein with exo- and endo-glycohydrolase activity that liberates free ADP-ribose and PAR chains, respectively. It interacts with various Poly(ADP-ribose) polymerase (PARP) proteins to facilitate appropriate and timely DNA repair. The balance between PARP and PARG activity is essential for efficient DDR. Inhibition of PARG lead to altered DNA repair in cancer cells. We have identified highly potent PARG inhibitors with picomolar IC50 in biochemical assay. PARG is the primary enzyme for dePARylation and accounts for 90% of dePARylation activity. Treatment of HCC-1806 cells with PARG inhibitors showed dose dependent increase of PARylation signature, with sub micromolar IC50 . Compounds also demonstrate significant functional, anti-proliferative activity in ovarian and breast cancer cell lines besides a favourable ADME profile. Further pharmacokinetic and pharmacodynamic characterization of the identified hits is currently in progress.